More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$140229766
EPS
-3.68
P/E ratio
--
Price to sales
0.41
Dividend yield
--
Beta
0.655782
Previous close
$12.97
Today's open
$12.98
Day's range
$12.26 - $12.98
52 week range
$9.22 - $13.63
show more
CEO
Daniel R. Chard
Employees
380
Headquarters
Baltimore, MD
Exchange
New York Stock Exchange
Shares outstanding
11182597
Issue type
Common Stock
Consumer Discretionary
Personal Services
Will Medifast's Metabolic Health Institute Strengthen Its Edge?
MED advances its metabolic health strategy through a new Institute, proprietary science and Trilivy's phased wellness system.
Zacks Investment Research • Nov 10, 2026

Medifast: 3 Key Takeaways for Long-Term Investors
Average revenue per active coach rose 54% year over year. Medifast ended the third quarter with $172.5 million in cash.
The Motley Fool • Nov 3, 2026

Medifast Is Running The Same Playbook, And I Have The Same Concerns
Medifast (MED) maintains a strong, cash-heavy balance sheet and trades near liquidation value, but its business model remains uninspiring amid GLP-1 disruption. Q3 2026 revenue declined 19.4% YoY to $72M, with active earning coaches down 47%, though average revenue per coach increased. Management transition and Steamboat Capital's activist involvement signal board-level changes, but the core product and MLM-style distribution remain unchanged.
Seeking Alpha • Oct 28, 2026

Medifast Q3 Loss Narrower Than Expected as Coach Productivity Rises
MED tops Q3 earnings expectations as coach productivity jumps 54.1% and margins expand, despite declining revenues and a shrinking coach network.
Zacks Investment Research • Oct 27, 2026

What Medifast (MED) Said on Its Q3 Earnings Call
Medifast NYSE: MED reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management said revenue was within its guidance range and marked a fourth consecutive quarter in which sales stabilized around the mid-$70 million range.
MarketBeat • Oct 26, 2026

Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript
Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 26, 2026

Medifast Announces Third Quarter 2026 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, today reported results for the third quarter ended September 30, 2026. Third Quarter 2026 Revenue: $72.0 million, with revenue per active earning coach of $7,064 Independent active earning coaches of 10,200 Net loss of $17.5 million (non-GAAP adjusted net loss of $2.1 million) Loss per diluted share ("EPS") of $1.57 (non-GAAP a.
Business Wire • Oct 26, 2026

Medifast (MED) Reports Q3 Loss, Tops Revenue Estimates
Medifast (MED) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.21 per share a year ago.
Zacks Investment Research • Oct 26, 2026

Medifast Q3 Earnings on the Horizon: Key Insights for Investors
MED's Q3 results are likely to face pressure from GLP-1 adoption, shrinking coach numbers and lower sales, while strategic initiatives may offer some support.
Zacks Investment Research • Oct 23, 2026

Why Is Weight Loss Different During Menopause? Common Myths Debunked
Myth: Menopause weight gain is inevitable. Truth: Acceleration is not inevitable.
GlobeNewsWire • Oct 15, 2026

¹ Disclosures

Open an M1 investment account to buy and sell MEDIFAST INC commission-free¹. Build wealth for the long term using automated trading and transfers.